Forte Biosciences (FRA:37T) Current Deferred Revenue: €0.00 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:37T Forte Biosciences Inc FRA:37T
33 GF Score
Price €65.50
! 3 Warning Signs
View Full Analysis

What is Forte Biosciences Current Deferred Revenue?

Forte Biosciences FRA:37T -0.76% 33 Current Deferred Revenue is €0.00 Mil as of Jun. 2026. GuruFocus rates FRA:37T with a GF Score™ of 33/100. The stock has 3 warning signs investors should review.

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Forte Biosciences's current deferred revenue for the quarter that ended in Jun. 2026 was €0.00 Mil.

Forte Biosciences Current Deferred Revenue Related Terms

Forte Biosciences Current Deferred Revenue Historical Data

* Premium members only.

The historical data trend for Forte Biosciences's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Forte Biosciences Current Deferred Revenue Chart

Forte Biosciences Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Deferred Revenue
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Forte Biosciences Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:37T
33GF Score
Forte Biosciences Inc FRA:37T
Current Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Revenue of €0.00 Mil mean?
Forte Biosciences (FRA:37T) has a Current Deferred Revenue of €0.00 Mil as of Jun. 2026. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Forte Biosciences and its competitors.
Is Forte Biosciences' Current Deferred Revenue too high?
Forte Biosciences' current Current Deferred Revenue is €0.00 Mil. Overall, Forte Biosciences has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Forte Biosciences' Current Deferred Revenue compare to WVE and SVRA?
Forte Biosciences' Current Deferred Revenue of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Revenue for a Biotechnology company?
A good Current Deferred Revenue depends on the Biotechnology industry context. However, Current Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Revenue mean?
A high Current Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Forte Biosciences and its competitors. Forte Biosciences's current Current Deferred Revenue is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Forte Biosciences stock overvalued right now?
Forte Biosciences (FRA:37T) has a current Current Deferred Revenue of €0.00 Mil. The current Current Deferred Revenue is €0.00 Mil. Forte Biosciences' overall GF Score™ is 33/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Revenue calculated?
Current Deferred Revenue is calculated from a company's financial statements. For Forte Biosciences (FRA:37T), the current Current Deferred Revenue is €0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Forte Biosciences Business Description

Other Exchanges FBRX:USA
Address 3060 Pegasus Park Drive, Building 6, Dallas, TX, USA, 75247
Forte Biosciences Inc is a clinical-stage biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. The Company is also advancing clinical development of FB102 in patient-based trials for non-segmental vitiligo and alopecia areata.
33GF Score

Get the complete analysis for FRA:37T

Current Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€65.50
Price